Table 2.
Deregulated miRNAs in selected studies considering distinct biofluids from patients with endometriosis, EAOC or HGSOC compared to control women.
| miRNAs in Biofluids | |||
|---|---|---|---|
| Reference | Gynaecological Condition | Biofluid Specimen | Main Deregulated miRNAs in Patients |
| [47] | Endometriosis | Peritoneal fluid | ↑ miR-106b-3p, miR-451a and miR-486-5p |
| [67] | Serum | ↓ let-7b and miR-135 | |
| [68] | Serum | ↓ miR-9 *, miR-141 *, miR-145 * and miR-542-3p ↑ miR-122 and miR-199a |
|
| [69] | Serum | ↑ miR-122 and miR-199a | |
| [70] | Serum | ↓ miR-30c-5p, miR-127-3p, miR-99b-5p, miRNA-15b-5p and miRNA-20a-5p ↑ miR-424-3p and miR-185-5p |
|
| [71] | Plasma | ↓ miR-17-5p, miR-20a and miR-22 | |
| [72] | Plasma | ↓ miR-200a-3p, miR-200b-3p and miR-414-3p | |
| [73] | Plasma | ↑ miR-154-5p | |
| [74] | EAOC | Plasma | Three distinct miRNA signatures, including ↑ miR-15b, miR-16, miR-21, and miR-195 |
| [75] | HGSOC | Serum | ↑ miR-1290 |
| [76] | Serum | ↓ miR-375 + CA-125 levels | |
| [77] | Serum | ↑ miR-1246 | |
| [78] | Serum | ↑ miR-200b, miR-200c | |
↑, up-regulated levels; ↓ down-regulated levels; CA-125, cancer antigen 125.